. Author manuscript; available in PMC: 2011 Jul 1.

Published in final edited form as: Biochem Pharmacol. 2010 Mar 3;80(1):122–128. doi: 10.1016/j.bcp.2010.02.020

Table 4.

Pharmacokinetic parameters estimated for 5-MeO-DMT and its active metabolite, bufotenine, in wild-type and Tg-CYP2D6 mice, after i.p. administration of 20 mg/kg 5-MeO-DMT.

	5-MeO-DMT		Bufotenine

	Wild-type	Tg-CYP2D6	Wild-type	Tg-CYP2D6
C_max (µmol/L)	18.3 ± 2.8	18.7 ± 0.9	0.210 ± 0.054	0. 331 ± 0.064^*
T_max (min)	7.5 ± 2.9	6.3 ± 2.5	21.3 ± 11.8	27.5 ± 5.0
AUC_0→∞(µmol·min/L)	650 ± 78	568 ± 72	14.4 ± 0.8	23.4 ± 1.0^*
T_1/2 (min)	13.4 ± 1.0	13.4 ± 1.4	25.4 ± 5.3	18.5 ± 1.5
MRT (min)	27.2 ± 3.2	23.1 ± 3.6	55.8 ±6.7	52.8 ± 3.4

P < 0.05, compared with the corresponding values in wild-type mice.